C
CTCX
vs
S&P 500
S&P 500
Over the past 12 months, CTCX has underperformed S&P 500, delivering a return of -30% compared to the S&P 500's +14% growth.
Stocks Performance
CTCX vs S&P 500
Performance Gap
CTCX vs S&P 500
Performance By Year
CTCX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Carmell Corp
Glance View
Carmell Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 10 full-time employees. The company went IPO on 2021-07-29. Carmell Corporation, formerly Carmell Therapeutics Corporation, is a regenerative medicine platform company. The firm is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. Its lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing its core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
